search
Back to results

Conventional vs Bipolar SIJ RFA for Treatment of Sacroiliac Joint Pain

Primary Purpose

Sacroiliac Joint Complex, Low Back Pain

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)
Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)
Sponsored by
University of Utah
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sacroiliac Joint Complex focused on measuring Sacroiliac Joint

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult participants aged 18-90 years old with at least 3 months of low back pain who have not responded to at least 3 months of conservative treatment.
  • 7-day average NPRS for low back pain of at least 4/10 at baseline
  • Pain relieved by at least 50% by either a fluoroscopically-guided intraarticular sacroiliac joint injection including a local anesthetic and a fluoroscopically-guided PSN block or dual fluoroscopically-guided PSN blocks.
  • Participants capable of understanding and providing consent in English and capable of complying with the outcome instruments used.

A pain diary with appropriate diagnostic categories of relief (100% relief, 80-99% relief, etc.), will be provided. Duration of pain relief will not be used as it has been shown to only marginally improve diagnostic confidence (17).

Exclusion Criteria:

  • History of SIJ fusion.
  • Symptomatic hip osteoarthritis
  • Active lumbar radicular pain
  • Evidence of hardware loosening (in participants with history lumbar or lumbosacral fusion).
  • Presence of pacemaker or neurostimulator.
  • Chronic widespread pain or somatoform disorder (e.g., fibromyalgia).
  • More than 50 mg morphine-equivalent per day opioid use.
  • Active bacterial infection or treatment of infection with antibiotics within the past 4 weeks.
  • Medical conditions causing significant functional disability (e.g., stroke, COPD).
  • Addictive behavior, severe clinical depression, or psychotic features.
  • History of anaphylactic reaction to any medication used.
  • Those receiving remuneration for their pain treatment (e.g., disability, worker's compensation).
  • Those involved in active litigation relevant to their pain.
  • The participant is incarcerated.

Sites / Locations

  • University of Utah Farmington Health CenterRecruiting
  • University of Utah Orthopaedic CenterRecruiting
  • University of Utah South Jordan Health CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)

Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)

Arm Description

N-SIJRFA - using a bipolar "palisade" technique to create a continuous strip lesion.

C-SIJRFA - using conventional monopolar periforaminal technique

Outcomes

Primary Outcome Measures

Change in Percent in NPRS Pain Score
The proportion of participants with ≥50% change in NPRS pain score at the 3-month follow-up assessment.

Secondary Outcome Measures

Percent of Relief
The proportion of participants with ≥50%, relief of pain by NPRS
Percent of Relief
The proportion of participants with ≥50%, relief of pain by NPRS
Percent of Relief
The proportion of participants with ≥50%, relief of pain by NPRS
Percent of Relief
The proportion of participants with ≥50%, relief of pain by NPRS
ODI Reduction
The proportion of participants who report ≥15-point ODI reduction
ODI Reduction
The proportion of participants who report ≥15-point ODI reduction
ODI Reduction
The proportion of participants who report ≥15-point ODI reduction
ODI Reduction
The proportion of participants who report ≥15-point ODI reduction
ODI Reduction
The proportion of participants who report ≥15-point ODI reduction
EQ-5D Improvement
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
EQ-5D Improvement
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
EQ-5D Improvement
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
EQ-5D Improvement
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
EQ-5D Improvement
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
PGIC Improvement
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale
PGIC Improvement
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale
PGIC Improvement
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale
PGIC Improvement
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale
PGIC Improvement
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale

Full Information

First Posted
June 3, 2022
Last Updated
April 27, 2023
Sponsor
University of Utah
Collaborators
Stratus Medical, INC
search

1. Study Identification

Unique Protocol Identification Number
NCT05409443
Brief Title
Conventional vs Bipolar SIJ RFA for Treatment of Sacroiliac Joint Pain
Official Title
Conventional or Bipolar Radiofrequency Ablation for the Treatment of Sacroiliac Joint Pain? The COBRA-SIJ Study, a Double-blinded, Randomized, Comparative Trial.
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 15, 2022 (Actual)
Primary Completion Date
August 30, 2025 (Anticipated)
Study Completion Date
June 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Utah
Collaborators
Stratus Medical, INC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Specific Aims The sacroiliac joint complex (SIJC) is a diathrodial, synovial joint and posterior ligamentous network that receives both anterior innervation from the lumbosacral plexus as well as posterior sensory innervation via the posterior sacral network (PSN). The PSN is comprised by the lateral branches S1-S3 posterior rami, with variable contributions from S4 lateral branch, L4 medial branch, and L5 dorsal ramus. Pain signals originating from the SIJC can be interrupted with image-guided percutaneous radiofrequency ablation (RFA) of the PSN, thereby reducing pain and disability in carefully selected patients. A prior systematic review estimated that 32-89% of patients achieve at least 50% pain relief for six months after some type of PSN ablation. Many experts suspect that heterogenous RFA techniques and technology are responsible for the variable success rates seen across published studies. Cadaveric work suggests that targeting the PSN with a large bipolar strip lesions would result in >95% PSN neural capture compared to a smaller lesion produced by a conventional, monopolar, periforaminal RFA technique which may capture as low as 2.5% of the PSN. Nimbus is a commonly used multi-tined RFA probe whose large bipolar lesion size make it an ideal option for complete PSN neural ablation. Both the Nimbus (N-SIJRFA) and conventional (C-SIJRFA) techniques and technologies are commonly used; however, there are no prospective RCT's comparing them, and the clinical significance remains unknown. Problem: There are no randomized controlled trials comparing novel technologies like N-SIJRFA to C-SIJRFA. Purpose: To compare pain and disability outcomes in patients with confirmed SIJC pain after randomization to either N-SIJRFA or C-SIJRFA. Central Hypothesis: N-SIJRFA will be more effective in improving pain and function compared to patients treated with C-SIJRFA at 3, 6, 12, 18, and 24 months. Specific Aims: Compare the proportion of participants who report ≥50% relief of pain by Numeric Pain Rating Scale (NPRS) after N-SIJRFA versus C-SIJRFA. Compare the proportion of participants who report ≥15-point ODI (Oswestry Disability Index) reduction after N-SIJRFA versus C-SIJRFA. Compare the proportion of participants with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) defined by ≥0.03, after N-SIJRFA versus C-SIJRFA. Compare the proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale after N-SIJRFA versus C-SIJRFA. Evaluate the differences in success rates for pain improvement, functional improvement and satisfaction in those experiencing ≥ 50%, ≥ 80%, and 100% pain relief after either prognostic PSN blocks or intra-articular (IA) sacroiliac joint (SIJ) injections. Determine the effect of PSN ablation on reducing pain related sleep disturbance as measured by the Pain and Sleep Questionnaire (PSQ-3). Compare procedural time requirements between those treated with N-SIJRFA versus C-SIJRFA. Report adverse effects. Report rates of subsequent interventional healthcare utilization including repeat N-SIJRFA versus C-SIJRFA, SIJ injection, and SIJ fusion.
Detailed Description
Low back pain affects the majority of individuals at some time in their lives. The estimated point prevalence of low back pain in 2015 was 7.3%, indicating that 540 million may be affected at any given time (1). The etiology of low back pain may be multifactorial but commonly is often attributed to nociception arising sacroiliac joint complex (SIJC) in as many as 15-30% of patients (2). The SIJC is a diathrodial, synovial joint that receives both anterior innervation from the lumbosacral plexus as well as posterior sensory innervation via the posterior sacral network (PSN) (3). The PSN is comprised by the lateral branches S1-S3 posterior rami, with variable contributions from S4 lateral branch, L4 medial branch, and L5 dorsal ramus (3-6). These have been targeted for neurotomy most commonly with image-guided percutaneous radiofrequency ablation (RFA) (7), but also with percutaneous cryoneurolysis (8), chemical neurolysis (9), endoscopic-guided RFA (10), and MRI high frequency ultrasound treatment (MRI-HIFU) (11). Prior systematic review has suggested that 32-89% of patients may achieve at least 50% pain relief for six months, while 11-44% of patients achieved 100% pain relief for the same period (12). Although elements of patient selection likely affect this estimate (13), studies have used a variety of different RFA techniques to target the PSN which also may impact success rates. Few studies have directly compared these techniques, but cadaveric work has suggested that targeting the PSN with bipolar strip lesions results in substantially higher rates of neural capture compared to periforaminal RFA performed with conventional monopolar electrodes (6). Further, the rate of complete neural capture with a periforaminal conventional monopolar RFA may be as low as 12.5%, which is perhaps one reason why some clinical studies have shown increased probability of success in groups treated with technologies known to create larger lesions (13,14). Similar effectiveness has been observed for periforaminal techniques with both conventional monopolar compared to larger cooled monopolar lesions (15), as well as between large continuous-lesion multi-electrode lesioning compared to periforaminal conventional monopolar technique (16). However, no study has directly compared a bipolar strip lesion using a "palisade" technique (N-SIJRFA) to a conventional monopolar periforaminal method, the latter of which is used commonly in many practice settings. The primary purpose of the current study is to evaluate the effectiveness of RFA of the PSN using a bipolar "palisade" technique to create a continuous strip lesion compared to conventional monopolar periforaminal technique in the treatment of patients with sacroiliac joint complex pain. Given the findings of recent cadaveric studies, the results of the proposed work may substantially impact the current treatment paradigm for PSN neurotomy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sacroiliac Joint Complex, Low Back Pain
Keywords
Sacroiliac Joint

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
To compare pain and disability outcomes in patients with confirmed SIJC pain after randomization to either N-SIJRFA or C-SIJRFA.
Masking
ParticipantOutcomes Assessor
Masking Description
Participants will be blinded to the group to which they are randomized. Given inherent approach differences between techniques, the physician performing the procedure cannot be blinded. However, staff responsible for outcome collection will remain blinded.
Allocation
Randomized
Enrollment
116 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)
Arm Type
Active Comparator
Arm Description
N-SIJRFA - using a bipolar "palisade" technique to create a continuous strip lesion.
Arm Title
Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)
Arm Type
Active Comparator
Arm Description
C-SIJRFA - using conventional monopolar periforaminal technique
Intervention Type
Procedure
Intervention Name(s)
Nimbus Sacroiliac Joint Radiofrequency Ablation (N-SIJRFA)
Intervention Description
Electrodes are positioned along the lateral sacral crest lateral to the inflection points of the S1, S2 and S3 lateral foraminal walls along first to third transverse sacral tubercles maintaining a craniocaudal line with an interelectrode distance of no more than 15mm. The appropriate locations are confirmed in both AP and lateral views and the tines are deployed. Following injection of lidocaine, lesions are performed at 85 degrees Celsius for 180 seconds at each site for bipolar sites and 80 degrees Celsius for 90 seconds for the monopolar site. Following ablation, the tines are retracted for all electrodes prior to removal.
Intervention Type
Procedure
Intervention Name(s)
Conventional Sacroiliac Joint Radiofrequency Ablation (C-SIJRFA)
Intervention Description
To target the L4 medial branch and L5 dorsal ramus, an electrode will be placed in parallel between the junction of the L5 transverse process and superior articular process and the sacral ala and S1 superior articular process. A periforaminal electrode position will be used to target the lateral branches from S1 to S3. An 22-G cannula with a 5-mm exposed tip will be directed to a location approximately 3-5mm lateral to the PSFA of S1, S2, and S3. The "analog clock" positions for the probes at S1 and S2 levels will be 1:00, 3:00, and 5:30 on the right, and 6:30, 9:00, and 11:00 on the left. For the S3 level the positions at 1:30 and 4:30 on the right, and 7:30 and 10:30 on the left will be used (6,18). The appropriate locations are confirmed in both AP and lateral views. Following injection of lidocaine, monopolar RFA is performed for 90 seconds at 80 degrees Celsius at each location.
Primary Outcome Measure Information:
Title
Change in Percent in NPRS Pain Score
Description
The proportion of participants with ≥50% change in NPRS pain score at the 3-month follow-up assessment.
Time Frame
3 month
Secondary Outcome Measure Information:
Title
Percent of Relief
Description
The proportion of participants with ≥50%, relief of pain by NPRS
Time Frame
6 month
Title
Percent of Relief
Description
The proportion of participants with ≥50%, relief of pain by NPRS
Time Frame
12 month
Title
Percent of Relief
Description
The proportion of participants with ≥50%, relief of pain by NPRS
Time Frame
18 month
Title
Percent of Relief
Description
The proportion of participants with ≥50%, relief of pain by NPRS
Time Frame
24 month
Title
ODI Reduction
Description
The proportion of participants who report ≥15-point ODI reduction
Time Frame
3 month
Title
ODI Reduction
Description
The proportion of participants who report ≥15-point ODI reduction
Time Frame
6 month
Title
ODI Reduction
Description
The proportion of participants who report ≥15-point ODI reduction
Time Frame
12 month
Title
ODI Reduction
Description
The proportion of participants who report ≥15-point ODI reduction
Time Frame
18 month
Title
ODI Reduction
Description
The proportion of participants who report ≥15-point ODI reduction
Time Frame
24 month
Title
EQ-5D Improvement
Description
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
Time Frame
3 month
Title
EQ-5D Improvement
Description
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
Time Frame
6 month
Title
EQ-5D Improvement
Description
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
Time Frame
12 month
Title
EQ-5D Improvement
Description
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
Time Frame
18 month
Title
EQ-5D Improvement
Description
The proportion of patients with clinically significant improvement in the categorical EuroQol 5 Dimensions tool (EQ-5D) (20) defined by ≥0.03 following treatments
Time Frame
24 month
Title
PGIC Improvement
Description
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale
Time Frame
3 month
Title
PGIC Improvement
Description
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale
Time Frame
6 month
Title
PGIC Improvement
Description
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale
Time Frame
12 month
Title
PGIC Improvement
Description
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale
Time Frame
18 month
Title
PGIC Improvement
Description
The proportions of participants who report being "improved" or "much improved" on the Patient Global Impression of Change (PGIC) scale
Time Frame
24 month

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult participants aged 18-90 years old with at least 3 months of low back pain who have not responded to at least 3 months of conservative treatment. 7-day average NPRS for low back pain of at least 4/10 at baseline Pain relieved by at least 50% by either a fluoroscopically-guided intraarticular sacroiliac joint injection including a local anesthetic and a fluoroscopically-guided PSN block or dual fluoroscopically-guided PSN blocks. Participants capable of understanding and providing consent in English and capable of complying with the outcome instruments used. A pain diary with appropriate diagnostic categories of relief (100% relief, 80-99% relief, etc.), will be provided. Duration of pain relief will not be used as it has been shown to only marginally improve diagnostic confidence (17). Exclusion Criteria: History of SIJ fusion. Prior SIJ RFA procedure Symptomatic hip osteoarthritis Active lumbar radicular pain Evidence of hardware loosening (in participants with history lumbar or lumbosacral fusion). Presence of pacemaker or neurostimulator. Chronic widespread pain or somatoform disorder (e.g., fibromyalgia). More than 50 mg morphine-equivalent per day opioid use. Active bacterial infection or treatment of infection with antibiotics within the past 4 weeks. Medical conditions causing significant functional disability (e.g., stroke, COPD). Addictive behavior, severe clinical depression, or psychotic features. History of anaphylactic reaction to any medication used. Those receiving remuneration for their pain treatment (e.g., disability, worker's compensation). Those involved in active litigation relevant to their pain. The participant is incarcerated.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
PMR Research Group
Phone
801-587-5488
Email
PMR.Research@hsc.utah.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Aaron Conger, DO
Phone
801-587-5488
Email
aaron.conger@hsc.utah.edu
Facility Information:
Facility Name
University of Utah Farmington Health Center
City
Farmington
State/Province
Utah
ZIP/Postal Code
84025
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
PMR Research Group
Phone
801-587-5432
Email
PMR.Research@hsc.utah.edu
First Name & Middle Initial & Last Name & Degree
Aaron Conger, DO
Phone
801-587-5488
Email
aaron.conger@hsc.utah.edu
Facility Name
University of Utah Orthopaedic Center
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84108
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
PMR Research Group
Phone
801-587-5432
Email
PMR.Research@hsc.utah.edu
First Name & Middle Initial & Last Name & Degree
Aaron Conger, DO
Phone
801-587-5488
Email
aaron.conger@hsc.utah.edu
Facility Name
University of Utah South Jordan Health Center
City
South Jordan
State/Province
Utah
ZIP/Postal Code
84009
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
PMR Research Group
Phone
801-587-5432
Email
PMR.Research@hsc.utah.edu
First Name & Middle Initial & Last Name & Degree
Aaron Conger, DO
Phone
801-587-5488
Email
aaron.conger@hsc.utah.edu

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
27733282
Citation
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6. Erratum In: Lancet. 2017 Jan 7;389(10064):e1.
Results Reference
background
PubMed Identifier
23253394
Citation
Cohen SP, Chen Y, Neufeld NJ. Sacroiliac joint pain: a comprehensive review of epidemiology, diagnosis and treatment. Expert Rev Neurother. 2013 Jan;13(1):99-116. doi: 10.1586/ern.12.148.
Results Reference
background
PubMed Identifier
25304483
Citation
Roberts SL, Burnham RS, Ravichandiran K, Agur AM, Loh EY. Cadaveric study of sacroiliac joint innervation: implications for diagnostic blocks and radiofrequency ablation. Reg Anesth Pain Med. 2014 Nov-Dec;39(6):456-64. doi: 10.1097/AAP.0000000000000156.
Results Reference
background
PubMed Identifier
13478452
Citation
SOLONEN KA. The sacroiliac joint in the light of anatomical, roentgenological and clinical studies. Acta Orthop Scand Suppl. 1957;27:1-127. No abstract available.
Results Reference
background
PubMed Identifier
4282245
Citation
Bradley KC. The anatomy of backache. Aust N Z J Surg. 1974 Jul;44(3):227-32. doi: 10.1111/j.1445-2197.1974.tb04409.x. No abstract available.
Results Reference
background
PubMed Identifier
29415262
Citation
Roberts SL, Stout A, Loh EY, Swain N, Dreyfuss P, Agur AM. Anatomical Comparison of Radiofrequency Ablation Techniques for Sacroiliac Joint Pain. Pain Med. 2018 Oct 1;19(10):1924-1943. doi: 10.1093/pm/pnx329.
Results Reference
background
PubMed Identifier
32353665
Citation
Shih CL, Shen PC, Lu CC, Liu ZM, Tien YC, Huang PJ, Chou SH. A comparison of efficacy among different radiofrequency ablation techniques for the treatment of lumbar facet joint and sacroiliac joint pain: A systematic review and meta-analysis. Clin Neurol Neurosurg. 2020 Aug;195:105854. doi: 10.1016/j.clineuro.2020.105854. Epub 2020 Apr 19.
Results Reference
background
PubMed Identifier
33783380
Citation
Sahoo RK, Das G, Pathak L, Dutta D, Roy C, Bhatia A. Cryoneurolysis of Innervation to Sacroiliac Joints: Technical Description and Initial Results-A Case Series. A A Pract. 2021 Mar 30;15(4):e01427. doi: 10.1213/XAA.0000000000001427.
Results Reference
background
PubMed Identifier
34077624
Citation
Nouer Frederico T, Ferraro LHC, Lemos JD, Sakata RK. Chemical neurolysis of the lateral branches of the sacral dorsal rami for the treatment of chronic pain in the sacroiliac joint: Case report and description of the technique. Pain Pract. 2022 Jan;22(1):134-136. doi: 10.1111/papr.13046. Epub 2021 Jun 25. No abstract available.
Results Reference
background
PubMed Identifier
30921988
Citation
Ibrahim R, Telfeian AE, Gohlke K, Decker O. Endoscopic Radiofrequency Treatment of the Sacroiliac Joint Complex for Low Back Pain: A Prospective Study with a 2-Year Follow-Up. Pain Physician. 2019 Mar;22(2):E111-E118.
Results Reference
background
PubMed Identifier
31187230
Citation
Najafi A, Sartoretti E, Binkert CA. Sacroiliac Joint Ablation Using MR-HIFU. Cardiovasc Intervent Radiol. 2019 Sep;42(9):1363-1365. doi: 10.1007/s00270-019-02263-0. Epub 2019 Jun 11.
Results Reference
background
PubMed Identifier
25371349
Citation
Bogduk N. Commentary on King W, Ahmed S, Baisden J, Patel N, MacVicar J, Kennedy DJ. Diagnosis of posterior sacroiliac complex pain: a systematic review with comprehensive analysis of the published data. Pain Med. 2015 Feb;16(2):222-4. doi: 10.1111/pme.12615. Epub 2014 Nov 5. No abstract available.
Results Reference
background
PubMed Identifier
19587617
Citation
Cohen SP, Strassels SA, Kurihara C, Crooks MT, Erdek MA, Forsythe A, Marcuson M. Outcome predictors for sacroiliac joint (lateral branch) radiofrequency denervation. Reg Anesth Pain Med. 2009 May-Jun;34(3):206-14. doi: 10.1097/AAP.0b013e3181958f4b.
Results Reference
background
PubMed Identifier
28340063
Citation
Tinnirello A, Barbieri S, Todeschini M, Marchesini M. Conventional (Simplicity III) and Cooled (SInergy) Radiofrequency for Sacroiliac Joint Denervation: One-Year Retrospective Study Comparing Two Devices. Pain Med. 2017 Sep 1;18(9):1731-1744. doi: 10.1093/pm/pnw333.
Results Reference
background
PubMed Identifier
22688606
Citation
Cheng J, Pope JE, Dalton JE, Cheng O, Bensitel A. Comparative outcomes of cooled versus traditional radiofrequency ablation of the lateral branches for sacroiliac joint pain. Clin J Pain. 2013 Feb;29(2):132-7. doi: 10.1097/AJP.0b013e3182490a17.
Results Reference
background
PubMed Identifier
31747020
Citation
Speldewinde GC. Successful Thermal Neurotomy of the Painful Sacroiliac Ligament/Joint Complex-A Comparison of Two Techniques. Pain Med. 2020 Mar 1;21(3):561-569. doi: 10.1093/pm/pnz282.
Results Reference
background
Citation
Bogduk N. On the Rational Use of Diagnostic Blocks for Spinal Pain. Neurosurg Q. 2009 Jun;19(2):88-100.
Results Reference
background
PubMed Identifier
18648237
Citation
Cohen SP, Hurley RW, Buckenmaier CC 3rd, Kurihara C, Morlando B, Dragovich A. Randomized placebo-controlled study evaluating lateral branch radiofrequency denervation for sacroiliac joint pain. Anesthesiology. 2008 Aug;109(2):279-88. doi: 10.1097/ALN.0b013e31817f4c7c.
Results Reference
background
PubMed Identifier
18201937
Citation
Copay AG, Glassman SD, Subach BR, Berven S, Schuler TC, Carreon LY. Minimum clinically important difference in lumbar spine surgery patients: a choice of methods using the Oswestry Disability Index, Medical Outcomes Study questionnaire Short Form 36, and pain scales. Spine J. 2008 Nov-Dec;8(6):968-74. doi: 10.1016/j.spinee.2007.11.006. Epub 2008 Jan 16.
Results Reference
background
PubMed Identifier
23199409
Citation
Soer R, Reneman MF, Speijer BL, Coppes MH, Vroomen PC. Clinimetric properties of the EuroQol-5D in patients with chronic low back pain. Spine J. 2012 Nov;12(11):1035-9. doi: 10.1016/j.spinee.2012.10.030.
Results Reference
background
PubMed Identifier
22891194
Citation
Ayearst L, Harsanyi Z, Michalko KJ. The Pain and Sleep Questionnaire three-item index (PSQ-3): a reliable and valid measure of the impact of pain on sleep in chronic nonmalignant pain of various etiologies. Pain Res Manag. 2012 Jul-Aug;17(4):281-90. doi: 10.1155/2012/635967.
Results Reference
background
PubMed Identifier
33664386
Citation
Tonosu J, Oka H, Watanabe K, Abe H, Higashikawa A, Kawai T, Yamada K, Nakarai H, Tanaka S, Matsudaira K. Characteristics of the spinopelvic parameters of patients with sacroiliac joint pain. Sci Rep. 2021 Mar 4;11(1):5189. doi: 10.1038/s41598-021-84737-1.
Results Reference
background
PubMed Identifier
30887220
Citation
Tonosu J, Kurosawa D, Nishi T, Ito K, Morimoto D, Musha Y, Ozawa H, Murakami E. The association between sacroiliac joint-related pain following lumbar spine surgery and spinopelvic parameters: a prospective multicenter study. Eur Spine J. 2019 Jul;28(7):1603-1609. doi: 10.1007/s00586-019-05952-z. Epub 2019 Mar 18.
Results Reference
background

Learn more about this trial

Conventional vs Bipolar SIJ RFA for Treatment of Sacroiliac Joint Pain

We'll reach out to this number within 24 hrs